TC
ITCI icon

TFS Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

TFS Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-22,968
Closed -$639K – 1209
2016
Q1 		$639K Buy
+22,968
New +$765K 0.09% 380
2015
Q2 		– Sell
-15,822
Closed -$378K – 1105
2015
Q1 		$378K Buy
+15,822
New +$354K 0.04% 623
2014
Q3 		– Sell
-19,533
Closed -$329K – 1240
2014
Q2 		$329K Buy
+19,533
New +$323K 0.03% 801

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

TFS Capital's ITCI Position: Q2 2016 in Review

TFS Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2016, closing a stake of 22,968 shares — an estimated $639K sold.

TFS Capital first reported a position in ITCI in Q2 2014 and held it in 3 quarters. The position peaked at $639K in Q1 2016. 139 funds tracked by Wall St. Rank hold ITCI as of Q2 2016.

  • TFS Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2016 after selling out during the quarter.
  • TFS Capital sold 22,968 Intra-Cellular Therapies Inc. shares in Q2 2016, an estimated $639K.
  • TFS Capital first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 3 quarters.
  • TFS Capital's Intra-Cellular Therapies Inc. position peaked at $639K in Q1 2016.
  • 139 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.